{"page":{"totalFilteredElements":84},"studies":[{"active":true,"description":"<div>A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma</div>","eudractNumber":"2020-000562-41","id":7242,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT04989803","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2023-01-01T13:39:41+01:00","shortTitle":"KT-US-499-0150","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells</div>","eudractNumber":"2020-005843-21","id":7303,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD19","id":"mt_55"}],"nctNumber":"NCT05041309","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-02-16T13:40:47+01:00","shortTitle":"KT-US-982-5968","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"<p class=\"MsoNormal\" align=\"center\" style=\"text-align:left;\">A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib\n(LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in\nPreviously Treated Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma\n(BRUIN CLL-322)</p>","eudractNumber":"2021-000043-49","id":9343,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT04965493","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-02-02T11:43:44+01:00","shortTitle":"LOXO-BTK-20022","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"<p>Histologische, immunph&#228;notypische und molekulargenetische\nCharakterisierung kutaner\nLymphom </p>","eudractNumber":null,"id":2695,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2014-10-14T09:41:37+02:00","shortTitle":"Lymphomsequenzierung","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)</div>","eudractNumber":null,"id":7962,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT05578976","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-07-20T13:49:14+02:00","shortTitle":"M20-621","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>Non-Hodgkin Lymphoma: Epcoritamab in Combination with Anti-Neoplastic Agents</div>","eudractNumber":"2021-005725-24","id":7304,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT05283720","phase":{"id":"ph_15","name":"Phase IB/II"},"recruitmentStart":"2023-12-19T13:51:13+01:00","shortTitle":"M22-132","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<div>First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies</div>","eudractNumber":"2023-503594-38","id":8892,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05753501","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2024-10-25T13:53:15+02:00","shortTitle":"M23-647","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"Phase III, Multicenter, Open label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide versus investigator choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma","eudractNumber":"2022-501810-77","id":8724,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06006117","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-17T09:09:16+02:00","shortTitle":"MARSUN","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the \nEfficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab \nVedotin Plus R-CHP in Treatment-na&#239;ve Participants With GCB Subtype of Diffuse Large \nB-cell Lymphoma (DLBCL)","eudractNumber":"2024-515526-89","id":11240,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-07-03T14:23:52+02:00","shortTitle":"MK2140-011","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>Constructing and validation of a robust, affordable, and widely applicable real-world outcome predictor for risk-tailored therapy for DLBCL patients in the German healthcare system</div>","eudractNumber":null,"id":11186,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06526065","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-02-13T15:10:35+01:00","shortTitle":"MMML-Predict","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}